Brought to you by 
Series B round for Phase Bioscience raises $25mm; closed at $48.4mm
13 Aug 2012
Executive Summary
Phase Bioscience (developing cost-effective production technology to purify protein and peptide therapeutics, improving their efficacy and side-effect profiles) has closed its Series B venture round. Johnson & Johnson Development Corp. Hatteras Venture Partners, and Fletcher Spaght Ventures brought in the initial $4mm. The company will use the proceeds to continue developing purification and drug delivery technologies acquired from Duke University. In connection with the financing, a member of J&J Development Corp. will take a seat on Phase Bioscience's board.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series B round for Phase Bioscience raises $25mm; closed at $48.4mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice